2invest AG
SYGNIS AG announces the launch of TrueHelix
DGAP-News: SYGNIS AG / Key word(s): Market launch Press Release SYGNIS AG announces the launch of TrueHelix – TrueHelix establishes SYGNIS as a reference in next generation – The TruePure tool addresses sample contamination, a key pitfall in – SYGNIS reinforces its client focused marketing approach by providing Madrid, Spain, and Heidelberg, Germany, February 2, 2017 – SYGNIS AG (Frankfurt: LIO1; ISIN: DE000A1RFM03; Prime Standard) today announced the launch of TrueHelix a new bioinformatics service platform, delivered through a dedicated web portal, for Next Generation Sequencing (NGS) providers and customers to analyze their sequencing data. The service platform strengthens SYGNIS’ position in the NGS user market and facilitates a service approach, which complements and supports SYGNIS’ genomic product range by addressing the key customer needs. In oncology, like with any other clinical application, confirmation that the amplified sample to be analyzed is free from contamination is vital and adds significant value for the end user. TruePure is the first tool in a range of services that SYGNIS intends to launch in 2017. These services will position SYGNIS as a reference company in the NGS bioinformatics. For further information, please contact:
Raimund Gabriel
SYGNIS AG is specialized in the development and the commercialization of proprietary technologies and offers a wide range of different commercial products addressing key challenges in molecular biology. With the acquisition of Expedeon Holdings, Ltd. based in Cambridge, UK, SYGNIS has added a complementary proteomic product portfolio. Resulting from this significant expansion, SYGNIS’ product portfolio now covers the entire workflow of molecular biology. The products are sold through a direct sales force and several distribution partners in Europe, the US and Asia. SYGNIS AG has offices in Germany, Spain and the UK, production sites in the UK and the US as well as sales offices in Asia. The company is listed on the German Stock Exchange in Frankfurt in the Prime Standard segment (Ticker: LIO1; ISIN: DE000A1RFM03). ### This publication is intended for information only and constitutes neither an offer to sell nor an invitation to buy securities. Some statements included in this press release, relating neither to proven financial results nor other historical data, should be viewed as forward-looking, i.e. not definite. Such statements are mainly predictions of future results, trends, plans or goals. These statements should not be considered to be total guarantees since given their very nature they are subject to known and unknown risks and imponderability and can be affected by other factors as a consequence of which the actual results, plans and goals of SYGNIS AG may deviate greatly from the established conclusions or implied predictions contained in such statements. SYGNIS does not undertake to publicly update or revise these statements in the light of new information or future results or for any other reason.###
02.02.2017 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG. |
Language: | English |
Company: | SYGNIS AG |
Waldhofer Str. 104 | |
69123 Heidelberg | |
Germany | |
Phone: | +49 (0) 6221 3540 125 |
Fax: | +49 (0) 6221 3540 127 |
E-mail: | investors@sygnis.com |
Internet: | www.sygnis.com |
ISIN: | DE000A1RFM03 |
WKN: | A1RFM0 |
Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange |
End of News | DGAP News Service |